Clinical Potentials of miR-576-3p, miR-613, NDRG2 and YKL40 in Colorectal Cancer Patients.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Jun 2020
Historique:
received: 31 01 2020
entrez: 28 6 2020
pubmed: 28 6 2020
medline: 12 2 2021
Statut: epublish

Résumé

Colorectal cancer (CRC) is the most common type of gastrointestinal tract cancers. This investigation aim was to assess the expression of miR-576-3p and miR-613 in CRC patients in addition to NDRG2 and YKL40 serum levels determination to decide their diagnostic and prognostic significance. Sixty early diagnosed CRC patients prior to any treatment in addition to twelve healthy subjects were enrolled in this study. Blood samples were taken from subjects and allowed for clotting and centrifugation, then the collected sera were stored at -80ºC till it were used for detection of our molecular biomarkers. The mature miRNAs expressions (miR-576-3p and miR-613) were detected in serum by qRT-PCR, while NDRG2 and YKL40 serum levels were determined by ELISA. In addition, the correlation of the measured parameters with the clinicopathological data of the patients was investigated. The study results showed that both miRNA-576-3p and miRNA-613 were down-regulated in CRC patients with fold change 0.33, 0.36; respectively. A significant positive correlation was observed between miR-576-3p and miR-613 (r = 0.75, p < 0.001). NDRG2 serum levels were decreased in patients compared to the control group but the decrease wasn't statistically significant. On the other hand, it was observed that YKL40 serum level was significantly increased in CRC patients compared to control (p-value < 0.001). Furthermore, YKL40 showed a very high diagnostic value (AUC = 0.97, specificity = 91.7%, sensitivity = 96%, p-value = 0.0001). The observations of this investigation concluded that, the expressions of miR-576-3p and miR-613 in addition to YKL40 serum levels determinations may help in the diagnosis of CRC.

Identifiants

pubmed: 32592365
doi: 10.31557/APJCP.2020.21.6.1689
pmc: PMC7568881
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
CHI3L1 protein, human 0
Chitinase-3-Like Protein 1 0
MIRN576 microRNA, human 0
MIRN613 microRNA, human 0
MicroRNAs 0
NDRG2 protein, human 0
Tumor Suppressor Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1689-1695

Références

J Histochem Cytochem. 2007 Dec;55(12):1213-28
pubmed: 17712177
PLoS One. 2018 Aug 16;13(8):e0202579
pubmed: 30114287
Nucleic Acids Res. 2014 Jan;42(Database issue):D68-73
pubmed: 24275495
Adv Surg. 2011;45:31-44
pubmed: 21954677
BMC Cancer. 2007 Oct 12;7:192
pubmed: 17935612
Biochem Biophys Res Commun. 2016 Jan 15;469(3):633-8
pubmed: 26703210
Oncotarget. 2016 Jun 28;7(26):39907-39915
pubmed: 27223438
J Cancer. 2017 Jan 1;8(1):48-56
pubmed: 28123597
Biomed Pharmacother. 2014 Oct;68(8):935-42
pubmed: 25451164
Biochem Biophys Res Commun. 2011 Mar 25;406(4):534-8
pubmed: 21352815
Tumour Biol. 2016 Apr;37(4):4383-91
pubmed: 26499784
Clin Exp Dermatol. 2016 Jun;41(4):346-51
pubmed: 26299703
Carcinogenesis. 2012 Oct;33(10):1882-8
pubmed: 22696597
Mol Cells. 2015;38(2):130-7
pubmed: 25556372
J Med Screen. 2007;14(3):132-7
pubmed: 17925085
PLoS One. 2012;7(2):e32368
pubmed: 22393400
World J Biol Chem. 2014 Aug 26;5(3):301-7
pubmed: 25225598
Leuk Res. 2013 Jun;37(6):647-56
pubmed: 23522449
Mol Endocrinol. 2011 Apr;25(4):584-96
pubmed: 21310851
Biochem Biophys Res Commun. 2019 Aug 6;515(4):734
pubmed: 31239039
Mol Cancer Ther. 2011 May;10(5):742-51
pubmed: 21357475
Mol Cancer Ther. 2011 Jan;10(1):47-56
pubmed: 21220491
Future Oncol. 2009 Sep;5(7):1065-82
pubmed: 19792974
Tumour Biol. 2016 May;37(5):6477-83
pubmed: 26631045
Cell Oncol (Dordr). 2016 Apr;39(2):139-47
pubmed: 26744345
Int J Cancer. 2009 Jan 1;124(1):7-15
pubmed: 18844221
Curr Cancer Drug Targets. 2004 Aug;4(5):455-61
pubmed: 15320720
Lancet. 2010 Mar 20;375(9719):1030-47
pubmed: 20304247
Biochem Biophys Res Commun. 2016 May 13;473(4):987-992
pubmed: 27049311
Biochem J. 2002 Jul 1;365(Pt 1):119-26
pubmed: 12071845
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
Clin Chim Acta. 2011 Apr 11;412(9-10):709-12
pubmed: 21272568
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202
pubmed: 16492905
Urol Oncol. 2008 Jan-Feb;26(1):47-52
pubmed: 18190830
FEBS Lett. 2014 Mar 3;588(5):705-12
pubmed: 24444603
Clin Immunol. 2011 Sep;140(3):268-75
pubmed: 21546314
J Exp Clin Cancer Res. 2010 Jul 30;29:103
pubmed: 20673333
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Transl Med. 2012 Nov 20;10:228
pubmed: 23164426
Gene. 2012 Jul 15;503(1):48-55
pubmed: 22565195
World J Gastroenterol. 2015 Jul 21;21(27):8284-92
pubmed: 26217080

Auteurs

Manal Nasreddin Eldaly (MN)

Department of Biochemistry, Faculty of Science, Helwan University, Cairo, Egypt.

Fateheya Mohamed Metwally (FM)

Department of Environmental & Occupational Medicine, National Research Centre, Cairo, Egypt.

Wafaa Ghoneim Shousha (WG)

Department of Biochemistry, Faculty of Science, Helwan University, Cairo, Egypt.

Abeer Salah El-Saiid (AS)

Department of Clinical & Chemical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.

Shimaa Shawki Ramadan (SS)

Department of Biochemistry, Faculty of Science, Helwan University, Cairo, Egypt.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH